Baseline demographic and clinical characteristics of patients with B-NHL who received loncastuximab tesirine (safety analysis set)
| Characteristic . | n (%) . | |
|---|---|---|
| All patients with B-NHL (N = 183) . | Patients with DLBCL (n = 139) . | |
| Sex | ||
| Female | 69 (37.7) | 59 (42.2) |
| Male | 114 (62.3) | 80 (57.6) |
| Age, y | ||
| Median | 63.0 | 63.0 |
| Range | 20-87 | 20-86 |
| ECOG score | ||
| 0-1 | 160 (87.4) | 119 (85.6) |
| 2 | 21 (11.5) | 18 (12.9) |
| 3 | 2 (1.1) | 2 (1.4) |
| B-NHL subtype | ||
| DLBCL group* | ||
| Double hit (MYC plus BCL-2 and/or BCL-6 rearrangement) | 20 (14.4) | |
| Triple hit (MYC plus BCL-2 and BCL-6 rearrangement) | 3 (2.2) | |
| Transformed | 37 (26.6) | |
| MCL | 15 (8.2) | — |
| FL | 14 (7.7)† | — |
| CLL | 6 (3.3) | — |
| Marginal zone B-cell lymphoma | 6 (3.3) | — |
| Burkitt lymphoma | 1 (0.5) | — |
| Waldenström macroglobulinemia | 1 (0.5) | — |
| Other | 1 (0.5)‡ | — |
| No. of lines of prior systemic therapy | ||
| Median | 3 | 3 |
| Range | 1-13 | 1-10 |
| First-line prior systemic therapy response | ||
| Relapsed after initial response | 115 (62.8) | 90 (64.7) |
| Refractory to first-line therapy | 43 (23.5) | 30 (21.6) |
| Last-line prior systemic therapy response | ||
| Relapsed after initial response | 66 (36.1) | 49 (35.3) |
| Refractory to last therapy line | 109 (59.6) | 83 (59.7) |
| Prior HCT | ||
| Autologous | 31 (16.9) | 22 (15.8) |
| Allogeneic | 5 (2.7) | 2 (1.4) |
| Both | 4 (2.2) | 2 (1.4) |
| Other§ | 2 (1.1) | 1 (0.7) |
| Prior CAR T-cell therapy | ||
| Yes | 3 (1.6) | 2 (1.4) |
| No | 180 (98.4) | 137 (98.6) |
| Serum LDH, U/L | ||
| Median | 323.0 | |
| Range | 109-9348 | |
| Characteristic . | n (%) . | |
|---|---|---|
| All patients with B-NHL (N = 183) . | Patients with DLBCL (n = 139) . | |
| Sex | ||
| Female | 69 (37.7) | 59 (42.2) |
| Male | 114 (62.3) | 80 (57.6) |
| Age, y | ||
| Median | 63.0 | 63.0 |
| Range | 20-87 | 20-86 |
| ECOG score | ||
| 0-1 | 160 (87.4) | 119 (85.6) |
| 2 | 21 (11.5) | 18 (12.9) |
| 3 | 2 (1.1) | 2 (1.4) |
| B-NHL subtype | ||
| DLBCL group* | ||
| Double hit (MYC plus BCL-2 and/or BCL-6 rearrangement) | 20 (14.4) | |
| Triple hit (MYC plus BCL-2 and BCL-6 rearrangement) | 3 (2.2) | |
| Transformed | 37 (26.6) | |
| MCL | 15 (8.2) | — |
| FL | 14 (7.7)† | — |
| CLL | 6 (3.3) | — |
| Marginal zone B-cell lymphoma | 6 (3.3) | — |
| Burkitt lymphoma | 1 (0.5) | — |
| Waldenström macroglobulinemia | 1 (0.5) | — |
| Other | 1 (0.5)‡ | — |
| No. of lines of prior systemic therapy | ||
| Median | 3 | 3 |
| Range | 1-13 | 1-10 |
| First-line prior systemic therapy response | ||
| Relapsed after initial response | 115 (62.8) | 90 (64.7) |
| Refractory to first-line therapy | 43 (23.5) | 30 (21.6) |
| Last-line prior systemic therapy response | ||
| Relapsed after initial response | 66 (36.1) | 49 (35.3) |
| Refractory to last therapy line | 109 (59.6) | 83 (59.7) |
| Prior HCT | ||
| Autologous | 31 (16.9) | 22 (15.8) |
| Allogeneic | 5 (2.7) | 2 (1.4) |
| Both | 4 (2.2) | 2 (1.4) |
| Other§ | 2 (1.1) | 1 (0.7) |
| Prior CAR T-cell therapy | ||
| Yes | 3 (1.6) | 2 (1.4) |
| No | 180 (98.4) | 137 (98.6) |
| Serum LDH, U/L | ||
| Median | 323.0 | |
| Range | 109-9348 | |
CLL, chronic lymphocytic leukemia; ECOG, Eastern Oncology Cooperative Group; LDH, lactate dehydrogenase; U/L, upper/lower.
DLBCL subtypes comprised DLBCL (n = 134), high-grade B-cell lymphoma (BCL; n = 2), aggressive BCL with features intermediate between DLBCL and Burkitt lymphoma (n = 1), mediastinal BCL (thymic large BCL; n = 1), and primary mediastinal BCL (n = 1). In the DLBCL category, transformed disease comprised FL (n = 26), marginal zone B-cell lymphoma (n = 2), lymphoplasmacytic lymphoma (n = 1), nodular lymphocyte-predominant Hodgkin lymphoma (n = 2), and Richter’s transformation (n = 6).
One patient with FL also had CLL/small lymphocytic lymphoma recurrence.
This patient had a history of DLBCL and was enrolled based on imaging consistent with recurrence. The patient was subsequently biopsied after enrollment, and the lesion determined to be sarcoid.
One patient with DLBCL underwent peripheral stem cell harvest transplantation, and 1 patient with FL underwent double cord transplantation.